It can involve insulin resistance, higher androgen levels, acne, facial hair growth, irregular ovulation, weight gain, inflammation, cholesterol changes, blood sugar problems, fatty liver risk, and increased cardiovascular risk
Tirazepatide (TZT), a dual glucagon-like peptide-1 (GLP-1)and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist may be effective in managing Covid-19-induced hyperglycemia in diabetic and non-diabetic patients
They require functional beta cells and are only approved for type 2 diabetes
Very common side effects (affecting more than 1 in 10 people) include nausea, diarrhoea, vomiting, constipation, and decreased appetite